Report Sections

See All Reports

  • HP:0000729: Autistic behavior
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0000729: Autistic behavior

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (32)


    Name (Synonyms) Correlation
    drug648 COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection Wiki 0.43
    drug644 COVID-19 RT-PCR Wiki 0.35
    drug635 COVID-19 FACILITY Wiki 0.30
    Name (Synonyms) Correlation
    drug637 COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA) Wiki 0.30
    drug2527 Placebo Infusion Wiki 0.30
    drug2777 RO6953958 Wiki 0.30
    drug3530 Treatment As Usual Wiki 0.30
    drug3949 lung ultrasound Wiki 0.30
    drug115 ASSIST Wiki 0.30
    drug2712 Pulse Oximeter Wiki 0.30
    drug3328 Symptoms questionnare Wiki 0.30
    drug3153 Social ABCs Wiki 0.30
    drug641 COVID-19 PCR and serology testing Wiki 0.30
    drug650 COVID-19 antibodies testing Wiki 0.30
    drug985 Daily Monitoring Wiki 0.30
    drug639 COVID-19 PCR Swab Wiki 0.30
    drug919 Cord Tissue Mesenchymal Stromal Cells Wiki 0.30
    drug1422 Group Social ABCs Wiki 0.30
    drug725 Cannabidivarin Wiki 0.30
    drug647 COVID-19 Swab Wiki 0.30
    drug1183 Emotional Support Plan Wiki 0.30
    drug341 Attention Training Program Wiki 0.30
    drug2425 Parents and Infants Engaged Wiki 0.30
    drug640 COVID-19 PCR and Serology Wiki 0.30
    drug3705 Wearable Medical Device (Empatica E4) Wiki 0.30
    drug1714 Interview by psychologists Wiki 0.30
    drug3115 Sham Attention Training Wiki 0.30
    drug2884 Responsive training with video feedback Wiki 0.30
    drug2883 Responsive training with no video feedback Wiki 0.30
    drug645 COVID-19 Serology Wiki 0.21
    drug1974 Matched Placebo Wiki 0.21
    drug2505 Placebo Wiki 0.01

    Correlated MeSH Terms (10)


    Name (Synonyms) Correlation
    D000067877 Autism Spectrum Disorder NIH 1.00
    D001321 Autistic Disorder NIH 0.90
    D002659 Child Development Disorders, Pervasive NIH 0.67
    Name (Synonyms) Correlation
    D065886 Neurodevelopmental Disorders NIH 0.43
    D001289 Attention Deficit Disorder with Hyperactivity NIH 0.30
    D004194 Disease NIH 0.24
    D006948 Hyperkinesis NIH 0.21
    D002658 Developmental Disabilities NIH 0.17
    D001523 Mental Disorders NIH 0.06
    D013315 Stress, Psychological NIH 0.06

    Correlated HPO Terms (3)


    Name (Synonyms) Correlation
    HP:0000717 Autism HPO 0.90
    HP:0007018 Attention deficit hyperactivity disorder HPO 0.30
    HP:0002487 Hyperkinetic movements HPO 0.21

    Clinical Trials

    Navigate: Correlations   HPO

    There are 11 clinical trials


    1 Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)

    This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.

    NCT03202303
    Conditions
    1. Autism Spectrum Disorder
    Interventions
    1. Drug: Cannabidivarin
    2. Drug: Matched Placebo
    MeSH:Autistic Disorder Autism Spectrum Disorder Child Development Disorders, Pervasive
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: Change in ABC-I from Baseline to Endpoint

    Measure: Aberrant Behavior Checklist-Irritability Subscale (ABC-I)

    Time: Change in ABC-I from Baseline to Week 12 (Change over 12 weeks)

    Secondary Outcomes

    Description: Change in RBS-R from Baseline to Endpoint

    Measure: Repetitive Behavior Scale-Revised (RBS-R)

    Time: Change in RBS-R from Baseline to Week 12 (Change over 12 weeks)

    Description: Change in ABC-SW from Baseline to Endpoint

    Measure: Aberrant Behavior Checklist-Social Withdrawal Subscale (ABC-SW)

    Time: Change in ABC-SW from Baseline to Week 12 (Change over 12 weeks)

    Description: Change in PedsQL from Baseline to Endpoint

    Measure: Pediatric Quality of Life Inventory (PedsQL) Family Impact Module

    Time: Change in PedsQL from Baseline to Week 12 (Change over 12 weeks)

    Description: Change in Vineland-3 from Baseline to Endpoint

    Measure: Vineland Adaptive Behavior Scale-3 (Vineland 3)

    Time: Change in Vineland-3 from Baseline to Week 12 (Change over 12 weeks)

    Description: Change in CGI-I from Baseline to Endpoint

    Measure: Clinical Global Impressions-Improvement (CGI-I)

    Time: Change in CGI-I from Baseline to Week 12 (Change over 12 weeks)

    Description: The MERS-R is designed to assess three domains of rigid behavior in children and adults with ASD: 1. Behavioral Rigidity (e.g., insistence on sameness, things must be done in his/her way, etc.) 2. Cognitive Rigidity (e.g., special interests, inflexible adherence to rules, etc.) 3. Protest (in response to deviation from rigidity; e.g., verbal objection, tantrum, physical aggression).

    Measure: Montefiore Einstein Rigidity Scale-Revised (MERS-R)

    Time: Change in MERS-R from Baseline to Week 12 (Change over 12 weeks)
    2 Evaluation of Social ABCs With Attention Training Intervention for Toddlers With Autism

    The Social ABCs is an evidence-based, developmentally informed, caregiver-mediated behavioural intervention for toddlers with suspected or confirmed Autism Spectrum Disorder (ASD). It is based on principles of Pivotal Response Treatment (PRT, grounded in Applied Behaviour Analysis), and responsive parenting. The two key targets of this program are functional verbal communication and positive caregiver-child affect sharing. This intervention takes place in the context of play and daily routines, and in all contexts is made to be fun, natural and motivating for the child. In both a pilot study and a recently completed randomized control trial, toddlers whose caregivers received training in the Social ABCs intervention showed significant gains in early language development (both responsivity and initiations), increased child smiling (mediated by parent smiling), and a trend toward increased social orienting (one important manifestation of social attention). Despite the social-communication benefits demonstrated through the Social ABCs, the research team is also motivated to foster the attentional abilities of toddlers with emerging ASD in response to compelling evidence that early attentional control abilities may play a central role in the emergence of ASD. Based on this knowledge, the current study targets not only social-communication challenges and affect sharing (as per the existing Social ABCs intervention), but also attentional control in toddlers with suspected or confirmed ASD. Using a structured, computerized attention-training protocol, this RCT evaluates the impact of supplementing the standard Social ABCs intervention with pre-intervention attentional control training.

    NCT03215394
    Conditions
    1. Autism Spectrum Disorder
    Interventions
    1. Behavioral: Attention Training Program
    2. Behavioral: Social ABCs
    3. Other: Treatment As Usual
    4. Behavioral: Sham Attention Training
    MeSH:Autistic Disorder Autism Spectrum Disorder
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: Reaction time in Gap-Overlap task (milliseconds)

    Measure: Improved Attentional Flexibility

    Time: Week 1 (baseline) and Week 6

    Description: Percentage of correct trials in a computer-based attention task (%)

    Measure: Improved Attentional Control

    Time: Week 1 (baseline) and Week 6

    Description: Percentage of intervals in which child is oriented to caregiver (%)

    Measure: Increased Social Orienting to Parent

    Time: Week 1 (baseline), Week 6, Week 18, and Week 30

    Description: Percentage of intervals in which caregiver and child are smiling together (%)

    Measure: Increased Child Smiling

    Time: Week 1 (baseline), Week 6, Week 18, and Week 30

    Description: Gains in proportion of appropriate child vocal responses, following a caregiver prompt (reported as percentage).

    Measure: Increased Child Responsivity to Parent Prompt

    Time: Week 1 (baseline), Week 6, Week 18, and Week 30

    Secondary Outcomes

    Description: Percentage of intervals during which parents demonstrate appropriate use of the Social ABCs techniques (%)

    Measure: Parent Fidelity of Implementation

    Time: Week 6, Week 18, and Week 30

    Description: Standard score on the Mullen Early Learning Scale (SS)

    Measure: Receptive Language

    Time: Week 0 and Week 30

    Description: Standard score on the Mullen Early Learning Scale (SS)

    Measure: Expressive Language

    Time: Week 0 and Week 30

    Description: Frequency of joint attentions bids on the Mini Early Social Communication (#)Scales

    Measure: Joint Attention

    Time: Week 0 and Week 30
    3 Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders

    This study entails a "proof of concept" evaluation of a novel intervention, Parents and Infants Engaged (PIE), for prodromal infants at-risk for neurodevelopmental disorders (NDs). The objectives of the current study are to examine whether the PIE intervention (a) transforms parent-infant transactions over time as intended, thereby facilitating increases in the time infants spend in joint engagement with their parents, and (b) is associated with improved social-communication functioning and positive changes in indices of autonomic self-regulation in infants at-risk for NDs.

    NCT03388294
    Conditions
    1. Autism Spectrum Disorder
    2. Neurodevelopmental Disorders
    Interventions
    1. Behavioral: Parents and Infants Engaged
    MeSH:Disease Autism Spectrum Disorder Neurodevelopmental Disorders
    HPO:Autistic behavior

    Primary Outcomes

    Description: This system entails continuous coding of infants' attention engagement into one of 6 mutually exclusive states: unengaged, onlooking, object engaged, person-engaged, supported joint engagement, and coordinated joint engagement. Due to the importance of the construct of engagement to our PIE theory of change, the total percent of time in joint engagement (supported + coordinated) will serve as the most proximal intervention outcome (i.e., changes expected at Posttest-1). Recent studies with children with NDs have shown that the coding system is sensitive to change in joint engagement after relatively short interventions.

    Measure: Change in Parent Child Engagement Coding from pretest to posttest 1

    Time: Baseline, posttest 1 (6-8 weeks after pretest)

    Description: This system entails continuous coding of infants' attention engagement into one of 6 mutually exclusive states: unengaged, onlooking, object engaged, person-engaged, supported joint engagement, and coordinated joint engagement. Due to the importance of the construct of engagement to our PIE theory of change, the total percent of time in joint engagement (supported + coordinated) will serve as the most proximal intervention outcome (i.e., changes expected at Posttest-1). Recent studies with children with NDs have shown that the coding system is sensitive to change in joint engagement after relatively short interventions.

    Measure: Change in Parent Child Engagement Coding from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Secondary Outcomes

    Description: The MSEL is a standardized developmental assessment for children birth to 58 months, frequently used in studies of children with NDs, and comprised of 4 scales: Fine Motor, Visual Reception, Receptive Language, and Expressive Language. The investigators will administer only the Receptive and Expressive Language subscales of the MSEL at the second posttest and the first follow up assessment. To be eligible for the intervention portion of the study, children have to score at least 1 s.d. below the mean on either the Receptive or Expressive Language subscale of the MSEL. The investigators will report t scores (Mean = 50, SD = 10)and the standardized total Early Learning Composite (Mean = 100, SD = 15). Higher scores indicate greater developmental skills.

    Measure: Change in Mullen Scales of Early Learning Receptive Language T-Scores from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: The MSEL is a standardized developmental assessment for children birth to 58 months, frequently used in studies of children with NDs, and comprised of 4 scales: Fine Motor, Visual Reception, Receptive Language, and Expressive Language. The investigators will administer only the Receptive and Expressive Language subscales of the MSEL at the second posttest and the first follow up assessment. To be eligible for the intervention portion of the study, children have to score at least 1 s.d. below the mean on either the Receptive or Expressive Language subscale of the MSEL. The investigators will report t scores (Mean = 50, SD = 10)and the standardized total Early Learning Composite (Mean = 100, SD = 15). Higher scores indicate greater developmental skills.

    Measure: Change in Mullen Scales of Early Learning Expressive Language T-scores from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: A play-based assessment used to measure children's approach-avoidance to novel sensory toys (i.e., hyper-reactivity) and orienting responses (i.e., hypo-reactivity) across three sensory modalities (auditory, visual, tactile). The investigators will report a mean score for Hypo (range = 1-5), Hyper (range = 1-5) sensory subscales. Higher scores indicate greater sensory differences in that domain (e.g. a high hypo domain score would indicate more hyposensitive reactions to sensory stimuli seen in the child).

    Measure: Change in Sensory Processing Assessment for Young Children from Pretest to Posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: A treatment response measure of social communication behaviors and other behaviors associated with autism spectrum disorder (ASD). Administration of the BOSCC involves a 12-minute video recorded interaction between an examiner and a young child using two standard sets of toys and play with bubbles. Behaviors are coded from video. Total score range is 16-80. Higher scores indicate more typical social communication skills, lower scores indicate poorer skills.

    Measure: Change in The Behavioral Observation of Social Communication Change (BOSCC) from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: Designed to measure the extent to which children will follow attentional cues of the examiner. Six prompts for attention following are embedded into the larger study protocol. Items are scored dichotomously as yes "1" or no "0".Total score range is 0-6. Higher scores indicate more typical responses to bids for joint attention.

    Measure: Change in The Attention Following Protocol (AF Protocol) from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: A parent report measure of children's expressive communication skills, such as vocabulary and pre-grammar abilities. The Words and Gestures (toddler) form will be used. Total words and gestures endorsed by parents will be reported. Greater words and gestures reported indicates larger expressive vocabulary.

    Measure: Baseline expressive communication level: The MacArthur-Bates Communicative Development Inventory

    Time: Baseline

    Description: A 43 item parent questionnaire that asks about the child's responses to various sensory stimuli in the context of functional activities and daily routines in the child's environment. It also documents strategies parents use to respond to their child's behaviors. Hyper and Hypo mean domain scores will be reported (range = 1-5). Greater domain scores indicate a greater presence of that type of sensory response.

    Measure: Change in The Sensory Experiences Questionnaire version 2.1 from pretest to posttest 1

    Time: Baseline, posttest 1 (6-8 weeks after pretest)

    Description: A 43 item parent questionnaire that asks about the child's responses to various sensory stimuli in the context of functional activities and daily routines in the child's environment. It also documents strategies parents use to respond to their child's behaviors. Hyper and Hypo mean domain scores will be reported (range = 1-5). Greater domain scores indicate a greater presence of that type of sensory response.

    Measure: Change in The Sensory Experiences Questionnaire version 2.1 from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: The Parental Stress Scale is a brief, 18-item scale designed to assess parent stress in nonclinical or clinical populations. It has acceptable levels of internal consistency (coefficient α = .83) and test-retest reliability (r = .81 over 6 weeks). It has good concurrent validity with the widely used Parent StressIndex (r =.75), which is a longer, more intrusive measure. A total score will be reported (range = 18-90).

    Measure: Baseline level of parent stress: Parental Stress Scale

    Time: Baseline

    Description: RSA levels will be collected using a standard protocol while the child is seated in a high chair exposed to social and non-social stimuli.

    Measure: Change in Respiratory sinus arrhythmia from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: Skin conductance levels will be collected using a standard protocol while the child is seated in a high chair exposed to social and non-social stimuli.

    Measure: Change in skin conductance levels from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: Parent-child interaction videos will be coded for parent responsiveness to child prelinguistic communication cues. These are each rated on a 0-7 scale. Higher scores indicate greater responsivity from parents.

    Measure: Change in Parent Responsiveness to Child Prelinguistic Communication Cues from pretest to posttest 1

    Time: Baseline, posttest 1 (6-8 weeks after pretest)

    Description: Parent-child interaction videos will be coded for parent responsiveness to child prelinguistic communication cues. These are each rated on a 0-7 scale. Higher scores indicate greater responsivity from parents.

    Measure: Change in Parent Responsiveness to Child Prelinguistic Communication Cues from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)

    Description: Parent-child interaction videos will be coded for parent responsiveness to child sensory reactivity cues. These are each rated on a 0-7 scale. Higher scores indicate greater responsivity from parents.

    Measure: Change in Parent Responsiveness to Child Sensory Reactivity Cues from pretest to posttest 1

    Time: Baseline, posttest 1 (6-8 weeks after pretest)

    Description: Parent-child interaction videos will be coded for parent responsiveness to child sensory reactivity cues. These are each rated on a 0-7 scale. Higher scores indicate greater responsivity from parents.

    Measure: Change in Parent Responsiveness to Child Sensory Reactivity Cues from pretest to posttest 2

    Time: Baseline, posttest 2 (13-16 weeks after pretest)
    4 Group Social ABCs: Early Intervention for Toddlers With Suspected ASD

    The Social ABCs is an evidence-based, developmentally informed, caregiver-mediated behavioural intervention for toddlers with suspected or confirmed Autism Spectrum Disorder (ASD). It is based on principles of Pivotal Response Treatment (PRT, grounded in Applied Behavioural Analysis), and responsive parenting. The two key targets of this program are functional verbal communication and positive caregiver-child affect sharing. This intervention takes place in the context of play and daily routines, and in all contexts is made to be fun. In both a pilot study and a recently completed randomized control trial, toddlers whose caregivers received training in the Social ABCs intervention showed significant gains in early language development (both responsivity and initiations), increased child smiling (mediated by parent smiling), and a trend toward increased social orienting (one important manifestation of social attention). In an effort to make the Social ABCs more feasible for community service providers to provide this intervention to higher number families, an abbreviated version of the Social ABCs intervention is being offered in a mixed group/individual format in a clinic setting. The primary goal of this pilot project is to assess feasibility of this abbreviated program in the novel format and setting. The secondary goal is to train clinical service providers to facilitate this intervention, thus introducing the program into community practice.

    NCT03499262
    Conditions
    1. Autism Spectrum Disorder
    2. Autism
    Interventions
    1. Behavioral: Group Social ABCs
    MeSH:Autistic Disorder Autism Spectrum Disorder
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: Change in proportion of appropriate child vocal responses following a caregiver prompt in 10-minute video observation

    Measure: Vocal Responsivity

    Time: Baseline, Week 6

    Secondary Outcomes

    Description: Change in rate of appropriate child-initiated vocalizations (Initiations); number per minute

    Measure: Vocal Initiations

    Time: Baseline, Week 6

    Description: Change in percentage of intervals with instances of social orienting (child looking at parent) per 10-minute video observation

    Measure: Social Orienting

    Time: Baseline, Week 6

    Description: Change in percent of correct strategy implementation by parents (Fidelity) per 10-minute video observation

    Measure: Caregiver Fidelity of Implementation

    Time: Baseline, Week 6
    5 A Phase II Study of hCT-MSC, an Umbilical Cord-Derived Mesenchymal Stromal Cell Product, in Children With Autism Spectrum Disorder

    The purpose of this Phase II study is to determine the efficacy of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) for improving social communication abilities in children with autism spectrum disorder (ASD).

    NCT04089579
    Conditions
    1. Autism
    2. Autism Spectrum Disorder
    Interventions
    1. Biological: Cord Tissue Mesenchymal Stromal Cells
    2. Other: Placebo Infusion
    MeSH:Disease Autistic Disorder Autism Spectrum Disorder Child Development Disorders, Pervasive
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: The primary outcome measure is the mean of the change on the Socialization and Communication Subscale Standard Scores on the Vineland Adaptive Behavior Scales (VABS-3). The primary endpoint is the change on this outcome measure from baseline to six months.

    Measure: Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales

    Time: Baseline, 6 months

    Secondary Outcomes

    Description: Change in VABS-3 (Vineland Adaptive Behavior Scales) Socialization Standard Score

    Measure: Change in VABS-3 Socialization Standard Score

    Time: Baseline, 6 months

    Description: Change in VABS-3 (Vineland Adaptive Behavior Scales) Communication Standard Score

    Measure: Change in VABS-3 Communication Standard Score

    Time: Baseline, 6 months

    Description: Clinical Global Impression- Severity Scale

    Measure: Change in CGI-Severity score

    Time: Baseline, 6 months

    Description: Clinical Global Impression- Impression

    Measure: CGI-Intervention score

    Time: Baseline, 6 months

    Description: Pediatric Quality of Life Scale

    Measure: Change in the Pediatric Quality of Life Scale

    Time: Baseline, 6 months

    Other Outcomes

    Description: Assess for infusion reactions

    Measure: Incidence and severity of infusion reactions

    Time: Baseline, 6 months

    Description: Assess for infections directly related to the study product infusions

    Measure: Incidence and severity of product-related infections

    Time: Baseline, 6 months

    Description: Assess for anti-HLA antibodies

    Measure: Evidence of formation of anti-HLA antibodies

    Time: Baseline, 6 months, 12 months

    Description: Assess for signs and symptoms of graft versus host disease

    Measure: Incidence and severity of graft versus host disease

    Time: 6 months, 12 months

    Description: Assess for study related and unexpected adverse events

    Measure: Incidence and severity of unexpected adverse events related to the study product

    Time: Baseline, 6 months, 12 months
    6 Project ASSIST: Advocating for Supports to Improve Service Transitions

    This is a randomized intervention study to test and develop the national curriculum of a parent intervention training targeting parent's ability for advocate for services to improve the transition to adulthood for their youth with autism spectrum disorder (ASD). UPDATE regarding COVID-19: The current intervention has been paused until it is safe to meet as a group again. We are still recruiting participants for cohort 2 (in TN and IL) and Cohort 1 and 2 (in WI), as the plan is to resume the intervention as soon as the situation allows and to keep the future scheduled interventions happening in the Fall of 2020, Fall of 2021 and Winter of 2022. For the baseline data collection visit, we have moved to remote data collection for all measures except the psychological testing with the youth - meaning that families will be able to partially complete baseline data via teleconference and/or phone calls and online surveys. In-person visits to complete the psychological testing with the youth will be scheduled in the future when it is safe to meet face to face.

    NCT04173663
    Conditions
    1. Autism Spectrum Disorder
    2. Autism
    Interventions
    1. Behavioral: ASSIST
    MeSH:Autistic Disorder Autism Spectrum Disorder
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: Examine whether ASSIST participation increases the intervention target of parental knowledge about adult service systems. A questionnaire created by the researchers (based on a measure developed to evaluate the VAP-T, Burke, Goldman, Hart, & Hodapp, 2016) will be used to measure parental knowledge about adult services. The questionnaire consists of 22 multiple-choice questions asking for factual information about adult disability services and the adult disability service system. The total score can range from 0 to 22. Higher scores indicate greater knowledge of the adult disability service system.

    Measure: Change in Parental Knowledge about adult services questionnaire

    Time: Baseline to initial follow-up (3 months after the intervention starts)

    Description: Examine whether ASSIST participation increases the intervention target of parental empowerment measured using the Family Empowerment Scale (FES; Koren, DeChillo, & Friesen, 1992). The 34-item questionnaire measures the extent to which parents feel empowered across three dimensions: family, the service system; and the larger community and political environment. Items are rated on a 5-point Likert Scale from 1= not at all true to 5 = very true. The total score can range from 34 to 170, with higher scores indicating greater empowerment.

    Measure: Change in Parental Empowerment Scale

    Time: Baseline to initial follow-up (3 months after the intervention starts)

    Description: Examine whether ASSIST participation increases the intervention target of parent advocacy skills measured by the Advocacy Skills and Comfort Scale (ASC; Burke, Goldman, Hart, & Hodapp, 2016). The 10-item measure assesses the degree to which parents feel comfortable and skilled in advocating for their offspring with ASD. Response options range from 1 = not at all to 5 = excellent. The total score can range from 10 to 50, with higher scores indicating more skills/comfort in advocating for their offspring.

    Measure: Change in Advocacy Skills and Comfort Scale

    Time: Baseline to initial follow-up (3 months after the intervention starts)

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family applied for.

    Measure: Change in Access to Services interview: Number of services the family applied for

    Time: Baseline to 12-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family is receiving.

    Measure: Change in Access to Services interview: Number of services the family is receiving

    Time: Baseline to 12-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of barriers to services that the family is experiencing / experienced.

    Measure: Change in Access to Services interview: Barriers to services

    Time: Baseline to 12-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in social participation for youth with ASD. Questions developed to measure social participation (Taylor, Adams, & Bishop, 2016) will be used to measure the social participation achievements of the youth participants before and after ASSIST per parent-report. This measure consists of 10 items with a 5-point Likert scale ranging from 0 = Less than yearly or never to 4 = Several times a week. The total score can range from 0 to 40, with higher scores indicating greater social participation for the youth with ASD.

    Measure: Social Participation Youth Outcomes

    Time: 12-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended 12 months after the intervention. The Vocational Index will be administered via structured interview.

    Measure: Post-Secondary Youth Outcomes

    Time: 12-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parent advocacy activities, measured using the Advocacy Activities measure (Taylor, Hodapp, Burke, Waitz-Kudla, & Rabideau, 2017).The 16-item instrument measures how frequently parents spend time in advocacy activities for the son/daughter with ASD. The response options range from 1 = not at all to 4 = very often. The total score can range from 16 to 64, with higher scores indicating greater parent participation in advocacy activities.

    Measure: Change in Advocacy Activities Scale

    Time: Baseline to 12-month post-intervention

    Secondary Outcomes

    Description: Examine whether ASSIST participation increases the intervention target of parental knowledge about adult service systems. A questionnaire created by the researchers (based on a measure developed to evaluate the VAP-T, Burke, Goldman, Hart, & Hodapp, 2016) will be used to measure parental knowledge about adult services. The questionnaire consists of 22 multiple-choice questions asking for factual information about adult disability services and the adult disability service system. The total score can range from 0 to 22. Higher scores indicate greater knowledge of the adult disability service system.

    Measure: Change in Parental Knowledge about adult services questionnaire

    Time: Baseline to 12-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parental knowledge about adult service systems. A questionnaire created by the researchers (based on a measure developed to evaluate the VAP-T, Burke, Goldman, Hart, & Hodapp, 2016) will be used to measure parental knowledge about adult services. The questionnaire consists of 22 multiple-choice questions asking for factual information about adult disability services and the adult disability service system. The total score can range from 0 to 22. Higher scores indicate greater knowledge of the adult disability service system.

    Measure: Change in Parental Knowledge about adult services questionnaire

    Time: Baseline to 18-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parental empowerment measured using the Family Empowerment Scale (FES; Koren, DeChillo, & Friesen, 1992). The 34-item questionnaire measures the extent to which parents feel empowered across three dimensions: family, the service system; and the larger community and political environment. Items are rated on a 5-point Likert Scale from 1= not at all true to 5 = very true. The total score can range from 34 to 170, with higher scores indicating greater empowerment.

    Measure: Change in Parental Empowerment Scale

    Time: Baseline to 12-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parental empowerment measured using the Family Empowerment Scale (FES; Koren, DeChillo, & Friesen, 1992). The 34-item questionnaire measures the extent to which parents feel empowered across three dimensions: family, the service system; and the larger community and political environment. Items are rated on a 5-point Likert Scale from 1= not at all true to 5 = very true. The total score can range from 34 to 170, with higher scores indicating greater empowerment.

    Measure: Change in Parental Empowerment Scale

    Time: Baseline to 18-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parent advocacy skills measured by the Advocacy Skills and Comfort Scale (ASC; Burke, Goldman, Hart, & Hodapp, 2016). The 10-item measure assesses the degree to which parents feel comfortable and skilled in advocating for their offspring with ASD. Response options range from 1 = not at all to 5 = excellent. The total score can range from 10 to 50, with higher scores indicating more skills/comfort in advocating for their offspring.

    Measure: Change in Advocacy Skills and Comfort Scale

    Time: Baseline to 12-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parent advocacy skills measured by the Advocacy Skills and Comfort Scale (ASC; Burke, Goldman, Hart, & Hodapp, 2016). The 10-item measure assesses the degree to which parents feel comfortable and skilled in advocating for their offspring with ASD. Response options range from 1 = not at all to 5 = excellent. The total score can range from 10 to 50, with higher scores indicating more skills/comfort in advocating for their offspring.

    Measure: Change in Advocacy Skills and Comfort Scale

    Time: Baseline to 18-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family applied for.

    Measure: Change in Access to Services interview: Number of services the family applied for

    Time: Baseline to 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family applied for.

    Measure: Change in Access to Services interview: Number of services the family applied for

    Time: Baseline to 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family applied for.

    Measure: Change in Access to Services interview: Number of services the family applied for

    Time: Baseline to 30-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family is receiving.

    Measure: Change in Access to Services interview: Number of services the family is receiving

    Time: Baseline to 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family is receiving.

    Measure: Change in Access to Services interview: Number of services the family is receiving

    Time: Baseline to 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of services that the family is receiving.

    Measure: Change in Access to Services interview: Number of services the family is receiving

    Time: Baseline to 30-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of barriers to services that the family is experiencing / experienced.

    Measure: Change in Access to Services interview: Barriers to services

    Time: Baseline to 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of barriers to services that the family is experiencing / experienced.

    Measure: Change in Access to Services interview: Barriers to services

    Time: Baseline to 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase access to services for youth with ASD transitioning from high school to adulthood. Using questions developed for the National Longitudinal Transition Study-2 (NLTS-2; Sanford et al., 2011), the investigators will collect data (via a semi-structured interview) on total number of barriers to services that the family is experiencing / experienced.

    Measure: Change in Access to Services interview: Barriers to services

    Time: Baseline to 30-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in social participation for youth with ASD. Questions developed to measure social participation (Taylor, Adams, & Bishop, 2016) will be used to measure the social participation achievements of the youth participants before and after ASSIST per parent-report. This measure consists of 10 items with a 5-point Likert scale ranging from 0 = Less than yearly or never to 4 = Several times a week. The total score can range from 0 to 40, with higher scores indicating greater social participation for the youth with ASD.

    Measure: Social Participation Youth Outcomes

    Time: Baseline

    Description: Test whether parent participation in the ASSIST intervention leads to increase in social participation for youth with ASD. Questions developed to measure social participation (Taylor, Adams, & Bishop, 2016) will be used to measure the social participation achievements of the youth participants before and after ASSIST per parent-report. This measure consists of 10 items with a 5-point Likert scale ranging from 0 = Less than yearly or never to 4 = Several times a week. The total score can range from 0 to 40, with higher scores indicating greater social participation for the youth with ASD.

    Measure: Social Participation Youth Outcomes

    Time: 30-month post-intervention

    Description: The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending. The Vocational Index will be administered via structured interview.

    Measure: Post-Secondary Youth Outcomes

    Time: Baseline

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended 6 months after the intervention. The Vocational Index will be administered via structured interview.

    Measure: Post-Secondary Youth Outcomes

    Time: 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended 24 months after the intervention. The Vocational Index will be administered via structured interview.

    Measure: Post-Secondary Youth Outcomes

    Time: 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended 30 months after the intervention. The Vocational Index will be administered via structured interview.

    Measure: Post-Secondary Youth Outcomes

    Time: 30-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in employment stability for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment that youth with ASD had before the intervention. The investigators will collect total number of jobs/positions that youth had. The Vocational Index will be administered via structured interview

    Measure: Post-Secondary Youth Outcomes: Employment stability

    Time: Baseline

    Description: Test whether parent participation in the ASSIST intervention leads to increase in employment stability for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment that youth with ASD had before the intervention. The investigators will collect total number of jobs/positions that youth had. The Vocational Index will be administered via structured interview

    Measure: Post-Secondary Youth Outcomes: Employment stability

    Time: 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in employment stability for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment that youth with ASD had before the intervention. The investigators will collect total number of jobs/positions that youth had. The Vocational Index will be administered via structured interview

    Measure: Post-Secondary Youth Outcomes: Employment stability

    Time: 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in employment stability for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment that youth with ASD had before the intervention. The investigators will collect total number of jobs/positions that youth had. The Vocational Index will be administered via structured interview

    Measure: Post-Secondary Youth Outcomes: Employment stability

    Time: 30-month post-intervention

    Description: The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended before ASSIST. The investigators will collect total number of hours per week spent in these activities.

    Measure: Post-Secondary Youth Outcomes: Hours spent in activity

    Time: Baseline

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended before and after ASSIST. Additionally, the investigators will collect total number of hours per week spent in these activities.

    Measure: Post-Secondary Youth Outcomes: Hours spent in activity

    Time: 6-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended before and after ASSIST. Additionally, the investigators will collect total number of hours per week spent in these activities.

    Measure: Post-Secondary Youth Outcomes: Hours spent in activity

    Time: 12-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended before and after ASSIST. Additionally, the investigators will collect total number of hours per week spent in these activities.

    Measure: Post-Secondary Youth Outcomes: Hours spent in activity

    Time: 24-month post-intervention

    Description: Test whether parent participation in the ASSIST intervention leads to increase in post-secondary vocational and educational participation for youth with ASD. The Vocational Index (Taylor & Seltzer, 2012) will be used to gather information on employment and post-secondary educational programs that youth with ASD are attending / attended before and after ASSIST. Additionally, the investigators will collect total number of hours per week spent in these activities.

    Measure: Post-Secondary Youth Outcomes: Hours spent in activity

    Time: 30-month post-intervention

    Description: Examine whether ASSIST participation increases the intervention target of parent advocacy activities, measured using the Advocacy Activities measure (Taylor, Hodapp, Burke, Waitz-Kudla, & Rabideau, 2017).The 16-item instrument measures how frequently parents spend time in advocacy activities for the son/daughter with ASD. The response options range from 1 = not at all to 4 = very often. The total score can range from 16 to 64, with higher scores indicating greater parent participation in advocacy activities.

    Measure: Change in Advocacy Activities Scale

    Time: Baseline to 30-month post-intervention
    7 Clinical Evolution and Parenting in Children and Adolescents With Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder Quarantined Because of Covid-19 Outbreak

    In response to the coronavirus disease 2019 (covid-19) outbreak, the home confinement of the population ordered by governments in many countries raise questions about its impact on individuals' physical and mental health in the short and longer term. In children, reduced physical activity, changes in lifestyle, disturbances in sleep patterns, lack of in-person contact with peers, poor or inadequate understanding of health risks may be risk factors of anxiety, stress, fatigue, sleep disorders (Brooks et al, 2020; Wang et al, 2020; Sprang et al, 2013). These problematic effects could be modulated by social factors (housing in urban or rural areas, availability of personal space at home, parenting stress, etc.) (Cluver et al, 2020; Liu et al, 2020).

    NCT04416360
    Conditions
    1. Autism Spectrum Disorder
    2. Attention-deficit Hyperactivity Disorder
    Interventions
    1. Other: Interview by psychologists
    MeSH:Hyperkinesis Disease Autistic Disorder Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder Child Development Disorders, Pervasive
    HPO:Attention deficit hyperactivity disorder Autism Autistic behavior Hyperactivity Hyperkinetic movements

    Primary Outcomes

    Description: composition, home confinement, change in the environment, personal room at home, screens with internet access, parents' current professional status, teleworking, care, family concerns related to Covid-19, parenting stress, schooling, recurrent complaints.

    Measure: Interview of the parents : contextual data

    Time: Baseline

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: Baseline

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: 1 month

    Description: related to education; related to daily family life; related to leisure, related to care (children/adolescents, parents)

    Measure: Interview of the children/adolescents/ parents : Experience of the confinement in general

    Time: 3 months

    Description: Data relating to disease and management of care. Experience of the referring caregiver.

    Measure: Interview of the referring caregiver : data relating to disease and management of care

    Time: 3 months
    8 Brain Imaging and Infant Development

    The aims of the BIBS Study The Brain Imaging in Babies study (BIBS) aims to improve understanding of how a baby's brain develops from before birth, up until 3-4 years of age. Working with children from a variety of backgrounds and communities, the investigators use a combination of state-of-the-art diagnostic tools such as MRI scans alongside traditional behavioural assessments to capture the earliest information on infant brain development. The focus of the BIBS study MRI scanning is a safe way of producing detailed images using strong magnetic fields and radio waves. It does not use X-ray. Along with learning more about brain development in general, the investigators also try to identify features that may in future help predict whether a child will or will not develop traits of conditions such as Autism Spectrum Disorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD). Long-term, this may help target useful interventions early on, helping children who are most in need. Since COVID-19 arrived in the United Kingdom (U.K.) in 2020, the investigators have been given ethical approval to include testing for this infection in the mothers and children participating in the study. This may provide an opportunity to better understand how mother and baby respond to infections. The investigators particularly welcome mothers who have had a positive COVID-19 test during their pregnancy to join the study.

    NCT04443179
    Conditions
    1. Autism Spectrum Disorder
    2. Attention Deficit Hyperactivity Disorder
    3. Neurodevelopmental Conditions
    4. COVID-19
    MeSH:Disease Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder
    HPO:Attention deficit hyperactivity disorder Autistic behavior

    Primary Outcomes

    Measure: Neurodevelopmental Outcomes

    Time: 3-4 years of age
    9 ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19 (Coronavirus Disease)

    The purpose of this study is to evaluate the feasibility, acceptability and effectiveness of a brief, telehealth intervention (the Emotional Support Plan), intended to support autistic adults to cope with their negative emotions during and/or after the COVID-19 pandemic. The first objective is to develop and refine a brief telehealth-delivered treatment, the Emotional Support Plan (ESP), to help promote adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic. The second objective is to assess the feasibility and effectiveness of the ESP to support autistic adults to implement emotion regulation strategies during periods of acute distress. The last objective is to yield preliminary data to apply for extramural grants to validate these methods to monitor and support mental health of autistic adults during key transitions (e.g., starting college).

    NCT04460677
    Conditions
    1. Psychological Distress
    2. Stress, Psychological
    3. Autism Spectrum Disorder
    Interventions
    1. Behavioral: Emotional Support Plan
    2. Behavioral: Daily Monitoring
    MeSH:Autistic Disorder Autism Spectrum Disorder Child Development Disorders, Pervasive Stress, Psychological
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: The PHQ-9, assessed weekly, is a 9-item questionnaire of psychological function over the past week with all items on a "0" (not at all) to "3" (nearly every day) scale. Higher scores equal more distress.

    Measure: Decreased distress on Patient Health Questionnaire (PHQ-9)

    Time: 8 week study period

    Description: EMA (Ecological Momentary Assessment) reports of decreased distress (in ESP + daily monitoring group only). Higher scores on the item equal higher levels of distress.

    Measure: Decreased distress on EMA reports

    Time: 8 week study period

    Description: The GAD-7, assessed weekly, is a 7-item questionnaire of anxiety symptoms over the past week with all items on a "0" (not at all) to "3" (nearly every day) scale. Higher scores equal more anxiety.

    Measure: Decreased anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7)

    Time: 8 week study period

    Secondary Outcomes

    Description: The ASR is a measure of adaptive functioning and psychopathology (e.g., anxiety, depression symptoms). Most of the items are on a 3 point scale including: (0) Not true, (1) Somewhat or sometimes true, and (2) Very often or often true.

    Measure: Adult Self Report (ASR)

    Time: 8 week study period
    10 A Randomized, Investigator- /Subject-blind, Single- and Multiple-ascending Dose, Placebo-controlled Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 Following Oral Administration in Healthy Male Participants

    This study will evaulate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single- and multiple-ascending doses (SAD and MAD) and food effect (FE) of RO6953958 following oral administration in healthy male participants.

    NCT04475848
    Conditions
    1. Autistic Disorder
    2. Autism Spectrum Disorder
    3. Child Development Disorders, Pervasive
    4. Mental Disorders
    5. Neurodevelopmental Disorders
    Interventions
    1. Drug: RO6953958
    2. Drug: Placebo
    MeSH:Disease Autism Spectrum Disorder Child Development Disorders, Pervasive Mental Disorders Autistic Disorder Neurodevelopmental Disorders Developmental Disabilities
    HPO:Autism Autistic behavior

    Primary Outcomes

    Measure: Percentage of Participants with Adverse Events in Part 1

    Time: From randomization up to 7 weeks (or up to 14 weeks if the participant is part of the food effect cohort)

    Measure: Percentage of Participants with Adverse Events in Part 2

    Time: From randomization up to 8 weeks

    Measure: Part 2: Change in suicide risk assessed using the Columbia Suicide Severity Rating Scale (C-SSRS)

    Time: From randomization up to 8 weeks

    Secondary Outcomes

    Measure: Part 1: Maximum Observed Plasma Concentration (Cmax) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1

    Measure: Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1

    Measure: Part 1: Last Quantifiable Concentration (Clast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Time To the Last Quantifiable Concentration (Tlast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Terminal Elimination Phase Half-Life (T1/2) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Area Under the Concentration-Time Curve from Time 0 to 12 hours (AUC(0-12h)) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Area Under the Concentration-Time Curve from Time Extrapolated to Infinity (AUC (0-inf)) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Apparent Clearance (CL/F) of RO6953958 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Apparent Volume of Distribution (V/F) of RO6953958 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Cumulative Amount of Unchanged Drug Excreted into the Urine (Ae) of RO6953958 and its Metabolites RO7021594 and RO7045755 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Fraction of the Administered Drug Excreted into the Urine (Fe) of RO6953958 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Part 1: Renal Clearance of the Drug from Urine (CLR) of RO6953958 in Fasted and Fed state

    Time: Day 1 to Day 5

    Measure: Parts 2: Cmax of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 and Day 10

    Measure: Parts 2: Molecular Weight Adjusted Metabolite-to-Parent Ratio for Cmax of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 and Day 10

    Measure: Parts 2: Average Plasma Concentration (Cavg) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: Tmax of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 and Day 10

    Measure: Part 2: Area Under the Concentration-Time Curve (AUC(0-t)) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: Molecular Weight Adjusted Metabolite-to-Parent Ratio for Area Under the Concentration-Time Curve (AUC(0-t)) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: T1/2 of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: CL/F of RO6953958

    Time: Day 1 to Day 14

    Measure: Part 2: V/F of RO6953958

    Time: Day 1 to Day 14

    Measure: Part 2: Ae of RO6953958

    Time: Day 1 to Day 14

    Measure: Part 2: Fe of RO6953958

    Time: Day 1 to Day 14

    Measure: Part 2: CLR of RO6953958

    Time: Day 1 to Day 14

    Measure: Part 2: Trough Plasma Concentration (Ctrough) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: Accumulation Ratio based on AUC (Rauc) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: Accumulation Ratio Based on Cmax (RCmax) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14

    Measure: Part 2: Accumulation Ratio based on Ctrough (RCtrough) of RO6953958 and its Metabolites RO7021594 and RO7045755

    Time: Day 1 to Day 14
    11 Parent Language Intervention for Autism

    As a result of the COVID-19 pandemic, telecoaching/telepractice models are of urgent importance. Given this, parents in the study will receive parent coaching through weekly video calls. To help us understand the best types of telecoaching, we will offer all participants responsive coaching, with half of the participants receiving an additional opportunity to reflect on their own use of language strategies with a therapist using video feedback and the other half receiving responsive coaching as usual, without video feedback. This information is important in helping us to understand the best way to coach parents using a telepractice model so that parents implement the intervention at high fidelity. Furthermore, we will aim to understand how parent learning style may also influence the implementation of these strategies.

    NCT04501588
    Conditions
    1. Autism Spectrum Disorder
    2. Autism
    Interventions
    1. Behavioral: Responsive training with no video feedback
    2. Behavioral: Responsive training with video feedback
    MeSH:Autistic Disord Autistic Disorder Autism Spectrum Disorder
    HPO:Autism Autistic behavior

    Primary Outcomes

    Description: Mother use of intervention strategies will be measured by transcribing and coding mother behaviors during 12-minute parent-child interactions, using a standard set of toys. The primary dependent variable will be the amount of correct strategy used expressed as a percentage correct. This is the percentage of child communication to which the adult responds correctly (i.e., contingently and within 5 seconds).

    Measure: Parent Use of Language Support Strategies (Mother-child interaction)

    Time: Two months after the start of the study

    Secondary Outcomes

    Description: Parent report of child's expressive vocabulary and prelinguistic communication skills

    Measure: MacArthur-Bates Communicative Development Inventory (MCDI) (Child)

    Time: Two months after the start of the study

    HPO Nodes


    HP:0000729: Autistic behavior
    Genes 557
    SNX14 PPM1D NLGN4X PIGY CAMTA1 TMEM231 SLC6A8 LIMK1 SOX3 CHD2 GJA5 CLCN4 MICOS13 LMAN2L TSC2 STS KCNAB2 SLC13A5 ARID1B SCN8A ND2 NLGN4X TCF4 NUS1 CLP1 ELN CNKSR2 SCN1A DEPDC5 SLC1A2 PWAR1 NLGN3 GABRG2 ATRX ADSL MED13L UCHL1 CHD2 TMEM138 GNAQ ADGRV1 RAB39B TSC1 DPYD ALDH18A1 SCN8A ARHGEF6 TBX1 SYNJ1 CDKL5 DYRK1A WWOX CHRNA7 TRAK1 SH2B1 NDUFS3 NDUFV2 IREB2 WDR26 EP300 ARX SPECC1L IL1RAPL1 DLG4 SHANK3 CACNA1C GABRA2 NDUFB11 EGF SLC25A22 ZC3H14 CLIP1 MTOR USP7 PIGQ GATAD2B BCOR CTCF MECP2 CUX2 TIMMDC1 MAPT NDUFAF8 NDUFB10 CACNA1B ANK3 C12ORF4 AFF2 NTNG2 RAD21 MCTP2 DDX3X NALCN ARVCF FBXO31 FLCN VPS13C RPS6KA3 MBOAT7 MED25 MID2 GABRG2 RERE KDM6B NDN TBR1 STS CUX2 NDUFS6 FOXRED1 MBOAT7 TRAPPC9 SKI SDHC HNRNPH2 TBR1 MED13 TAF1 NDUFAF4 WFS1 MED23 EXT2 TSPAN7 TBX2 IL1RAPL1 JAM2 TMEM216 SRP54 NEXMIF SCN1B ASXL3 EEF1A2 MAGEL2 KCNB1 SMC1A GTF2IRD1 UFD1 STAG1 NDUFS8 NDUFAF3 SNORD115-1 PIGV TMEM126B MED12 TBC1D23 CACNA1A GAMT SH2B1 RARS1 RFC2 DMXL2 GABRG2 SLC9A6 NTRK2 PPP2R5D GRN CC2D2A MEIS2 NDUFAF3 FOXP1 EP300 CLTC IQSEC2 ALG13 FRMPD4 ANKRD11 EXTL3 SIN3A SNRPN CACNA2D2 FGFR1 CLIP2 GRIA3 COMT NECAP1 HESX1 HCN1 SZT2 OPHN1 PIGP NHS JMJD1C TCF20 GRIA3 AARS1 FRRS1L UBA5 NDUFS2 TMLHE NDUFV1 PRSS12 PCGF2 NLGN3 KDM5B MED13L DMPK AUTS2 HIRA CDKL5 AP3B2 IQSEC2 CARS2 SYT1 YWHAG PGAP1 SRY STAG2 NAA10 CREBBP OTUD6B CHD2 TRRAP GNAO1 MAN1B1 RAB11B TM4SF20 PRODH UGP2 SEC23B RSRC1 ASH1L PARS2 ZNF41 ST3GAL3 IQSEC1 CXORF56 RERE EHMT1 AKT1 PCDH19 CNNM2 KCNA2 GABRD ZNF711 ALMS1 SYNGAP1 DEAF1 NDUFAF2 SYP SCN9A POMT1 GJA8 GDI1 KCNA1 SETD5 SLC9A7 PCDH19 CDKL5 TBX1 HECW2 TUSC3 NDUFB3 POLA1 PWRN1 USP7 KMT2A AIMP1 AP1S2 PTEN SATB2 ST3GAL3 FGF12 RPL10 IQSEC2 DHDDS GPHN CLCN4 PDE4D AHDC1 EDC3 BCKDK SCN2A SLC35C1 HDAC4 CRBN SEC24C TCF4 NEUROD2 PAH HIVEP2 MECP2 IPW ARFGEF2 KCNA2 HCN1 SLC25A12 GATM NR2F1 SCN2A SON SYNGAP1 MED12 HDAC8 PGAP2 NDUFS7 SCN1B MEIS2 SDHD C9ORF72 DNM1 RSPRY1 SHANK3 PIK3CA DHCR7 NDUFAF5 PTCHD1 TMEM237 SCN3A STXBP1 CHD1 CRADD SIM1 ACTL6B FTSJ1 MAPK8IP3 CDH15 ALG11 KMT5B POLA1 UPF3B LINS1 SMG9 ND3 HERC1 GRIN1 LHX1 PIGL ATP6V1A SETD2 SYNJ1 NIPBL TUBB3 HCFC1 KCNT1 PRDM16 VAMP2 MEF2C NEUROD2 ATP1A3 FTSJ1 DYM SNCA TBCK MEF2C SCN9A CXORF56 AUTS2 INTS1 RREB1 SLC45A1 SEMA3E ADNP TSC2 NTRK2 HNF1B PODXL NPAP1 CHD7 SNX14 SCN2A NAGA RSPRY1 BCORL1 TCF12 SMC3 SLC25A1 ACOX1 AGTPBP1 NDUFS1 PIGP GABRA1 CASK CTNNB1 LRRK2 RERE YY1 PRKAR1A DCPS NRXN1 TAF1 CHD8 PSMD12 WFS1 ACADL PIGC MECP2 CNKSR2 AP2M1 SARS1 NAA10 PARK7 CC2D1A HTRA2 BAZ1B PROKR2 KMT2C ND1 CYFIP2 NDUFS4 UBE3A TREM2 NDP TRIM8 SOX2 MECP2 C12ORF4 FOXP2 HERC2 TLK2 AP3B2 GP1BB ARX REV3L UBTF NONO EZR STXBP1 VCP ZNF423 NDUFAF4 NUS1 ADNP MKRN3-AS1 MSTO1 PTCHD1 ACSL4 NSUN2 TNIK PINK1 TET3 SLC6A8 KLLN GRIN2D DNM1 PLXND1 CLCN4 CDK8 ZIC1 GRIK2 GTF2I IFNG EXT2 SLC6A1 USP27X FMN2 ALDH5A1 DHCR7 THOC2 PDE4D RORA POGZ NAGA COG5 ZBTB20 FMR1 NDUFA6 SH2B1 EHMT1 PIGO FMR1 RPS23 HCN1 ARV1 ALG13 AGTR2 PIGL PACS2 PUF60 SLC35A3 NDUFS4 FOXG1 HERC2 PAK3 SQSTM1 TWNK CEP290 STXBP1 MKRN3 NDUFA1 TBX1 TBC1D24 NDUFA11 SYN1 CNTNAP2 PRKN SIM1 SETD5 OTUD6B NEXMIF FRMPD4 PACS1 DPYD ARNT2 PNKP B3GALNT2 NDST1 SNORD116-1 DOCK7 NDUFAF1 PPP3CA DLG3 GFM1 GABRB2 PPP2CA PDE4D CNTNAP2 HNMT TSC1 TRIO KDM5C SIK1 METTL23 WASHC4 STX1B TBL2 OTX2 RNF135 SDHB CTCF ZFPM2 PIGW DMD TMEM106B SNRPN SLC35A3 GABRD DEAF1 PSEN1 GABRB3 USF3 SCN1A NDUFB9 NDUFA13 GABRA5 CHMP2B MAOA NAA15 TECR SCN1A SMAD4 MAN1B1 MAPK10 UBA5 USP9X RAI1 NFIB PTEN KPTN PGAP3 PIGG SCN1B SPATA5 ALG13 PUF60 ZNF81 DNAJC6 NUBPL
    Protein Mutations 1
    S1009A
    SNP 1
    rs6971

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0000729: Autistic behavior
    Genes 557
    SNX14 PPM1D NLGN4X PIGY CAMTA1 TMEM231 SLC6A8 LIMK1 SOX3 CHD2 GJA5 CLCN4 MICOS13 LMAN2L TSC2 STS KCNAB2 SLC13A5 ARID1B SCN8A ND2 NLGN4X TCF4 NUS1 CLP1 ELN CNKSR2 SCN1A DEPDC5 SLC1A2 PWAR1 NLGN3 GABRG2 ATRX ADSL MED13L UCHL1 CHD2 TMEM138 GNAQ ADGRV1 RAB39B TSC1 DPYD ALDH18A1 SCN8A ARHGEF6 TBX1 SYNJ1 CDKL5 DYRK1A WWOX CHRNA7 TRAK1 SH2B1 NDUFS3 NDUFV2 IREB2 WDR26 EP300 ARX SPECC1L IL1RAPL1 DLG4 SHANK3 CACNA1C GABRA2 NDUFB11 EGF SLC25A22 ZC3H14 CLIP1 MTOR USP7 PIGQ GATAD2B BCOR CTCF MECP2 CUX2 TIMMDC1 MAPT NDUFAF8 NDUFB10 CACNA1B ANK3 C12ORF4 AFF2 NTNG2 RAD21 MCTP2 DDX3X NALCN ARVCF FBXO31 FLCN VPS13C RPS6KA3 MBOAT7 MED25 MID2 GABRG2 RERE KDM6B NDN TBR1 STS CUX2 NDUFS6 FOXRED1 MBOAT7 TRAPPC9 SKI SDHC HNRNPH2 TBR1 MED13 TAF1 NDUFAF4 WFS1 MED23 EXT2 TSPAN7 TBX2 IL1RAPL1 JAM2 TMEM216 SRP54 NEXMIF SCN1B ASXL3 EEF1A2 MAGEL2 KCNB1 SMC1A GTF2IRD1 UFD1 STAG1 NDUFS8 NDUFAF3 SNORD115-1 PIGV TMEM126B MED12 TBC1D23 CACNA1A GAMT SH2B1 RARS1 RFC2 DMXL2 GABRG2 SLC9A6 NTRK2 PPP2R5D GRN CC2D2A MEIS2 NDUFAF3 FOXP1 EP300 CLTC IQSEC2 ALG13 FRMPD4 ANKRD11 EXTL3 SIN3A SNRPN CACNA2D2 FGFR1 CLIP2 GRIA3 COMT NECAP1 HESX1 HCN1 SZT2 OPHN1 PIGP NHS JMJD1C TCF20 GRIA3 AARS1 FRRS1L UBA5 NDUFS2 TMLHE NDUFV1 PRSS12 PCGF2 NLGN3 KDM5B MED13L DMPK AUTS2 HIRA CDKL5 AP3B2 IQSEC2 CARS2 SYT1 YWHAG PGAP1 SRY STAG2 NAA10 CREBBP OTUD6B CHD2 TRRAP GNAO1 MAN1B1 RAB11B TM4SF20 PRODH UGP2 SEC23B RSRC1 ASH1L PARS2 ZNF41 ST3GAL3 IQSEC1 CXORF56 RERE EHMT1 AKT1 PCDH19 CNNM2 KCNA2 GABRD ZNF711 ALMS1 SYNGAP1 DEAF1 NDUFAF2 SYP SCN9A POMT1 GJA8 GDI1 KCNA1 SETD5 SLC9A7 PCDH19 CDKL5 TBX1 HECW2 TUSC3 NDUFB3 POLA1 PWRN1 USP7 KMT2A AIMP1 AP1S2 PTEN SATB2 ST3GAL3 FGF12 RPL10 IQSEC2 DHDDS GPHN CLCN4 PDE4D AHDC1 EDC3 BCKDK SCN2A SLC35C1 HDAC4 CRBN SEC24C TCF4 NEUROD2 PAH HIVEP2 MECP2 IPW ARFGEF2 KCNA2 HCN1 SLC25A12 GATM NR2F1 SCN2A SON SYNGAP1 MED12 HDAC8 PGAP2 NDUFS7 SCN1B MEIS2 SDHD C9ORF72 DNM1 RSPRY1 SHANK3 PIK3CA DHCR7 NDUFAF5 PTCHD1 TMEM237 SCN3A STXBP1 CHD1 CRADD SIM1 ACTL6B FTSJ1 MAPK8IP3 CDH15 ALG11 KMT5B POLA1 UPF3B LINS1 SMG9 ND3 HERC1 GRIN1 LHX1 PIGL ATP6V1A SETD2 SYNJ1 NIPBL TUBB3 HCFC1 KCNT1 PRDM16 VAMP2 MEF2C NEUROD2 ATP1A3 FTSJ1 DYM SNCA TBCK MEF2C SCN9A CXORF56 AUTS2 INTS1 RREB1 SLC45A1 SEMA3E ADNP TSC2 NTRK2 HNF1B PODXL NPAP1 CHD7 SNX14 SCN2A NAGA RSPRY1 BCORL1 TCF12 SMC3 SLC25A1 ACOX1 AGTPBP1 NDUFS1 PIGP GABRA1 CASK CTNNB1 LRRK2 RERE YY1 PRKAR1A DCPS NRXN1 TAF1 CHD8 PSMD12 WFS1 ACADL PIGC MECP2 CNKSR2 AP2M1 SARS1 NAA10 PARK7 CC2D1A HTRA2 BAZ1B PROKR2 KMT2C ND1 CYFIP2 NDUFS4 UBE3A TREM2 NDP TRIM8 SOX2 MECP2 C12ORF4 FOXP2 HERC2 TLK2 AP3B2 GP1BB ARX REV3L UBTF NONO EZR STXBP1 VCP ZNF423 NDUFAF4 NUS1 ADNP MKRN3-AS1 MSTO1 PTCHD1 ACSL4 NSUN2 TNIK PINK1 TET3 SLC6A8 KLLN GRIN2D DNM1 PLXND1 CLCN4 CDK8 ZIC1 GRIK2 GTF2I IFNG EXT2 SLC6A1 USP27X FMN2 ALDH5A1 DHCR7 THOC2 PDE4D RORA POGZ NAGA COG5 ZBTB20 FMR1 NDUFA6 SH2B1 EHMT1 PIGO FMR1 RPS23 HCN1 ARV1 ALG13 AGTR2 PIGL PACS2 PUF60 SLC35A3 NDUFS4 FOXG1 HERC2 PAK3 SQSTM1 TWNK CEP290 STXBP1 MKRN3 NDUFA1 TBX1 TBC1D24 NDUFA11 SYN1 CNTNAP2 PRKN SIM1 SETD5 OTUD6B NEXMIF FRMPD4 PACS1 DPYD ARNT2 PNKP B3GALNT2 NDST1 SNORD116-1 DOCK7 NDUFAF1 PPP3CA DLG3 GFM1 GABRB2 PPP2CA PDE4D CNTNAP2 HNMT TSC1 TRIO KDM5C SIK1 METTL23 WASHC4 STX1B TBL2 OTX2 RNF135 SDHB CTCF ZFPM2 PIGW DMD TMEM106B SNRPN SLC35A3 GABRD DEAF1 PSEN1 GABRB3 USF3 SCN1A NDUFB9 NDUFA13 GABRA5 CHMP2B MAOA NAA15 TECR SCN1A SMAD4 MAN1B1 MAPK10 UBA5 USP9X RAI1 NFIB PTEN KPTN PGAP3 PIGG SCN1B SPATA5 ALG13 PUF60 ZNF81 DNAJC6 NUBPL
    Protein Mutations 1
    S1009A
    SNP 1
    rs6971

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook